Lv55
1106 积分 2023-06-27 加入
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
1小时前
已完结
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
1天前
已完结
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study
10天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
16天前
已完结
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
23天前
已完结
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
28天前
已完结
2023 updated MASCC/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents
1个月前
已完结
Mitigating acute chemotherapy-associated adverse events in patients with cancer
1个月前
已完结
Oral Selective Estrogen Receptor Degrader for Advanced Breast Cancer
1个月前
已关闭
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer
1个月前
已关闭
皖公网安备34019202002308
